TOB2 INDUCES CLONOGENICITY AND PROLIFERATION IN CANCER CELLS AND A POTENTIAL BIOMARKER FOR DIFFERENT CANCER TYPES

Vol 2, 2021 - 142609
DR - Doctoral Student
Favorite this paper
How to cite this paper?
Abstract

INTRODUCTION AND OBJECTIVES: TOB2 (transducer of ERBB2, 2) is known as an antiproliferative protein involved in mRNA deadenylation and cell cycle arrest. Although TOB2 is considered a tumor suppressor, its role in tumor cells and tumor transformation is almost unknown. Our aim is to investigate the role of TOB2 modulation in proliferation, clonogenicicty and cell death in tumor and tumorigenic cells in vitro and to evaluate the impact of TOB2 expression in overall survival (OS) and relapse free-survival (RFS) in diferent tumor types. MATERIAL AND METHODS: MDA-MB-231, H460 and HEK293T cell lines were used in the study. Crystal violet and clonogenic assays were performed after TOB2 overexpression or inhibition by specific siRNA for 24h. Cell cycle profile and cell death (anexin V) were assesed after TOB2 overexpression for 24, 48 and 72h and both were analyzed by flow cytometry. Western blott was applied to evaluate the TOB2 transfection or inhibition efficiency. KMplotter data analysis was used to estimate the impact of TOB2 in OS and RFS in 21 cancer types (n=7489) using RNA-seq databases. RESULTS AND CONCLUSION: TOB2 overexpression in MDA-MB-231, H460 and HEK293T cells increased clonogenic potential and crystal violet cells stanning. Confirming these data, TOB2 inhibition showed opposite effect. However trypan blue assay suggests an increase in viable cells only in MDA-MB-231 and HEK293T cells after TOB2 overexpression. Interestingly, cell cycle analysis suggests that in the cells used in the study, TOB2 has no effect in supressing cell cycle progression. Moreover TOB2 has no impact in cell death. KM plotter analysis showed that high expression of TOB2 in breast cancer positively impacts in OS. In cervical squamous cell carcinoma, high expression of TOB2 impacts negatively in OS and in RFS. Esophageal adenocarcinoma and squamous cell carcinoma analysis demonstrates that high TOB2 expression is related to higher RFS and OS rates, respectively. In kidney renal clear cell carcinoma high TOB2 expression has positive effect in OS, meanwhile in kidney renal papillary cell carcinoma, high TOB2 expression impacts negatively in RFS. In ovarian cancer low TOB2 expression is associated to higher OS rates and in lung adenocarcinoma, high TOB2 expression has positive impact in RFS rates. In pancreatic ductal adenocarcinoma TOB2 lower expression is associated with higher OS and RFS rates, while in pheochromocytoma and paraganglioma low TOB2 expression is associated with lower OS probability. TOB2 higher expression in stomach adenocarcinoma is associated to higher OS and RFS, which is also observed in uterine corpus endometrial carcinoma OS. Our data show for the first time a pro-tumor TOB2 effect in neoplastic cells. Moreover, our analysis demonstrated that TOB2 may have different OS and RFS impact in different cancer types, suggesting that TOB2 can act as a tumor biomarker for a diverse tumor types.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Programa de Hemato-Oncologia Molecular, Laboratório de Hemato-Oncologia Celular e Molecular – Instituto Nacional de Câncer, Rio de Janeiro – Brasil
  • 2 Programa de Imunologia e Biologia Tumoral, Laboratório de Biologia Celular – Instituto Nacional de Câncer, Rio de Janeiro - Brasil
Track
  • 3. Molecular Biology
Keywords
TOB2
proliferation
biomarker
pro-tumor